<DOC>
	<DOCNO>NCT00582634</DOCNO>
	<brief_summary>- To determine docetaxel cisplatin administer dose intense manner adjuvant setting resect non-small cell lung cancer - To evaluate time progression overall survival - To evaluate toxicity chemotherapy combination adjuvant set - To correlate XPD ERCC1 polymorphisms time progression toxicity patient treat regimen</brief_summary>
	<brief_title>Adjuvant Cisplatin Docetaxel Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Stage IB IIIA nonsmall cell lung cancer completely resect within 4 8 week initiate treatment study Performance Status ECOG 0 1 Peripheral neuropathy : &lt; grade 1 Adequate blood cell count Adequate liver hepatic function Women childbearing potential must negative pregnancy test . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter Patients history severe hypersensitivity reaction DocetaxelÂ® drug formulate polysorbate 80 . Women breastfeed . Coexistent second malignancy history prior malignancy within previous 5 year ( exclude basal squamous cell carcinoma skin treat curatively ) Uncontrolled cardiac disease uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>non small cell lung cancer</keyword>
	<keyword>adjuvant</keyword>
	<keyword>cisplatin</keyword>
	<keyword>docetaxel</keyword>
</DOC>